PHILADELPHIA - In a study that could explain why some breast cancers are more aggressive than others, researchers say they now understand how cancer cells force normal cells to act like viruses - allowing tumors to grow, resist treatment, and spread. The virus mimic is detected in the blood of cancer patients, particularly in cases of an aggressive type known as triple-negative breast cancer. Researchers from the Perelman School of Medicine at the University of Pennsylvania say cracking the code of how this process works opens up the possibility of targeting this mechanism for treatment. They published their findings today in Cell.
In addition to cancer cells, human tumors also contain normal cells like fibroblasts and various immune cells. Cancer cells corrupt these cells to help tumors grow and spread, and to survive when attacked. The fibroblasts cause these tumors to show high levels of interferon-stimulated genes (ISGs), which are genes that normally fight off viruses. The fact that ISGs show up in tumors suggests something inside the tumors is mimicking a virus.
"The conundrum was that in most cases, there was no viral infection in these tumors," said the study's senior author Andy J. Minn, MD, PhD, an associate professor of Radiation Oncology at Penn. "We've been studying this problem for many years, and it's a puzzle we were motivated to solve because cancers with this kind of anti-viral signaling can be particularly aggressive."
It turns out the cancer cells instruct fibroblasts to secrete exosomes - tiny fluid filled sacs that in this case contain special genetic material that makes them look like viruses. Barzin Nabet, a graduate student and first author of the study, along with other members of Minn's team from the departments of Medicine and Surgery used breast cancer as a model and found that when cancer cells stimulate fibroblasts, the fibroblasts respond by secreting exosomes that are rich in a specific type of RNA known as RN7SL1.
Unlike most RNA in cells, RN7SL1 has a special end that resembles virus RNA. Under the direction of the breast cancer cells, the fibroblasts ensure the exosomes keep that viral-like end exposed, tricking the cells that take up the exosomes into responding as if there is a viral infection.
"The ability of cancer cells to specifically instruct the fibroblasts to expose the viral-like end of RN7SL1 is a key discovery," Minn said. "If the end remains covered, breast cancer cells wouldn't treat these exosomes like a virus, making them less likely to progress and more likely to respond to treatment. On the other hand, if the end is always exposed, cells would react as if they are infected with a virus all the time."
The ability of certain types of breast cancers to instruct fibroblasts in this way could explain why some breast cancers are more aggressive and inflammatory than others. Triple-negative breast cancer and BRCA1 cancer, two types known to be aggressive, are both more likely to active anti-viral responses than other less aggressive forms of breast cancer.
"Since we can test the blood of cancer patients to measure the presence of exposed RN7SL1 in exosomes, we can potentially identify patients whose cancers will be the most aggressive because of this virus mimic," Minn said. "Now that we understand how the exposed RNA is generated, we can look to potential therapeutic targets."
The current study, along with a previous related study from Minn's group, suggests the NOTCH pathway could be one of those potential drug targets. Drugs that block NOTCH can both turn off signals that instruct fibroblasts as well as interfere with the ability of breast cancer to respond to the virus mimic. Therapy that includes NOTCH inhibitors was effective at treating mice with triple-negative breast cancer.
This study was supported by the National Institutes of Health (F31CA189707, R01GM111959), a National Cancer Institute Cancer Center Support Grant (2-P30-CA-016520-35), the Breast Cancer Alliance Research Foundation, the Parker Institute for Cancer Immunotherapy, and the Basser Research Center for BRCA.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $6.7 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2016 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2016, Penn Medicine provided $393 million to benefit our community.